Research Papers

25 of 83 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Incurred Sample Reanalysis: Time to Change the Sample Size Calculation?
Rudzki PJ; Biecek P; Kaza M.
AAPS J (Unknown)
Published: 2019
1/6 Transparent
Funding Declared
Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?
Strik AS; Wang YC; Ruff LE; Yashar W; Messmer BT; Mould DR.
AAPS J (Unknown)
Published: 2018
1/6 Transparent
Therapeutic Potential of Engineered Extracellular Vesicles.
Mentkowski KI; Snitzer JD; Rusnak S; Lang JK.
AAPS J (Unknown)
Published: 2018
1/6 Transparent
Funding Declared
Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis.
Svensson EM; Acharya C; Clauson B; Dooley KE; Karlsson MO.
AAPS J (Unknown)
Published: 2016
1/6 Transparent
Funding Declared
Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions.
Margolskee A; Darwich AS; Galetin A; Rostami-Hodjegan A; Aarons L.
AAPS J (Unknown)
Published: 2015
1/6 Transparent
Funding Declared
Modeling Testosterone Circadian Rhythm in Hypogonadal Males: Effect of Age and Circannual Variations.
González-Sales M; Barrière O; Tremblay PO; Nekka F; Desrochers J; Tanguay M.
AAPS J (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and t…
Gill KL; Gardner I; Li L; Jamei M.
AAPS J (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling …
Musther H; Gill KL; Chetty M; Rostami-Hodjegan A; Rowland M; Jamei M.
AAPS J (Unknown)
Published: 2015
1/6 Transparent
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.
Rosengren S; Dychter SS; Printz MA; Huang L; Schiff RI; Schwarz HP; McVey JK; Drake FH; Maneval DC; Kennard DA; Frost GI; Sugarman BJ; Muchmore DB.
AAPS J (Unknown)
Published: 2015
1/6 Transparent
Funding Declared
Anti-repulsive Guidance Molecule C (RGMc) Antibodies Increases Serum Iron in Rats and Cynomolgus Monkeys by Hepcidin Do…
Böser P; Seemann D; Liguori MJ; Fan L; Huang L; Hafner M; Popp A; Mueller BK.
AAPS J (Unknown)
Published: 2015
3/6 Transparent
Data Funding Declared
Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid i…
Leander J; Almquist J; Ahlström C; Gabrielsson J; Jirstrand M.
AAPS J (Unknown)
Published: 2015
1/6 Transparent
Funding Declared
Scientific and regulatory standards for assessing product performance using the similarity factor, f2.
Stevens RE; Gray V; Dorantes A; Gold L; Pham L.
AAPS J (Unknown)
Published: 2015
1/6 Transparent
Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.
Andorko JI; Hess KL; Jewell CM.
AAPS J (Unknown)
Published: 2014
1/6 Transparent
Funding Declared
Statistical power calculations for mixed pharmacokinetic study designs using a population approach.
Kloprogge F; Simpson JA; Day NP; White NJ; Tarning J.
AAPS J (Unknown)
Published: 2014
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of i…
Han K; Jin J; Maia M; Lowe J; Sersch MA; Allison DE.
AAPS J (Unknown)
Published: 2014
1/6 Transparent
Diurnal variation in P-glycoprotein-mediated transport and cerebrospinal fluid turnover in the brain.
Kervezee L; Hartman R; van den Berg DJ; Shimizu S; Emoto-Yamamoto Y; Meijer JH; de Lange EC.
AAPS J (Unknown)
Published: 2014
2/6 Transparent
Funding Declared
Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinica…
Gervais D; Corn T; Downer A; Smith S; Jennings A.
AAPS J (Unknown)
Published: 2014
Comparison of methods for handling missing covariate data.
Johansson ÅM; Karlsson MO.
AAPS J (Unknown)
Published: 2013
1/6 Transparent
Funding Declared
Multiple imputation of missing covariates in NONMEM and evaluation of the method's sensitivity to η-shrinkage.
Johansson ÅM; Karlsson MO.
AAPS J (Unknown)
Published: 2013
1/6 Transparent
Funding Declared
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected…
Rekić D; Röshammar D; Bergstrand M; Tarning J; Calcagno A; D'Avolio A; Ormaasen V; Vigan M; Barrail-Tran A; Ashton M; Gisslén M; Äbelö A.
AAPS J (Unknown)
Published: 2012
2/6 Transparent
Funding Declared
Structure-based virtual screening for drug discovery: a problem-centric review.
Cheng T; Li Q; Zhou Z; Wang Y; Bryant SH.
AAPS J (Unknown)
Published: 2012
2/6 Transparent
Data Funding Declared
Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer.
Mahapatra S; Karnes RJ; Holmes MW; Young CY; Cheville JC; Kohli M; Klee EW; Tindall DJ; Donkena KV.
AAPS J (Unknown)
Published: 2011
1/6 Transparent
Funding Declared
A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer.
Avanti C; Amorij JP; Setyaningsih D; Hawe A; Jiskoot W; Visser J; Kedrov A; Driessen AJ; Hinrichs WL; Frijlink HW.
AAPS J (Unknown)
Published: 2011
Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibi…
Keizer RJ; Funahashi Y; Semba T; Wanders J; Beijnen JH; Schellens JH; Huitema AD.
AAPS J (Unknown)
Published: 2011
Multidimensional atomic force microscopy: a versatile novel technology for nanopharmacology research.
Lal R; Ramachandran S; Arnsdorf MF.
AAPS J (Unknown)
Published: 2010
1/6 Transparent
Funding Declared